Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome
Authors' conclusion
In this real-life study neridronate was associated with rapid and progressive improvement of symptoms of CRPS which was maintained up to 3 years of follow-up. The predictors of excellent response were early response, lower limb localisation, absence of predisposing events and male gender.
Study context
- Population
- Patients with type I complex regional pain syndrome (CRPS) treated with IV neridronate
- Participants
- 103 patients
- Outcome
- VAS pain change from baseline (baseline mean 79.1 mm)
- Follow-up
- M3 and M12
Methodological detailsreal-life, multivariable logistic regression
- Real-life
- Multivariable logistic regression
Main finding
As reported in the abstract
Mean VAS pain at baseline
79.1 mm
Change in VAS pain at M3
−45.9 mm, 95% CI 40.1 to 51.8
Change in VAS pain at M12
−61.6 mm, 95% CI 55.3 to 67.9
Observational data: associations, not effects.
Further findings
Resolution of hyperalgesia, allodynia and loss of motion · M12
- Hyperalgesia resolved
- 84.3%
- Allodynia resolved
- 88.1%
- Loss of motion resolved
- 53.5%
Predictors of excellent response
- Early VAS pain response at M3: chance of excellent response per 10 mm decrease
- 2.5 times
- Male gender (better)
- No predisposing event (better than any predisposing event)
- Lower limb site (better)
Original publication
Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome. Clin Exp Rheumatol. Published 20 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →